MaxCyte Signs Strategic Platform License With Lyell Immunopharma; Lyell Immunopharma Obtains Non-Eexclusive Clinical And Commercial Rights To Use MaxCyte's Technology; MaxCyte Receives Fees And Payments
Portfolio Pulse from Benzinga Newsdesk
MaxCyte has signed a strategic platform license with Lyell Immunopharma, granting Lyell non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte will receive licensing fees, clinical milestone payments, and sales-based payments.
July 06, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MaxCyte's partnership with Lyell Immunopharma and the subsequent licensing fees, clinical milestone payments, and sales-based payments could potentially boost MaxCyte's revenue.
The news directly pertains to MaxCyte and its financial prospects. The licensing agreement with Lyell Immunopharma could lead to an increase in MaxCyte's revenue through licensing fees, clinical milestone payments, and sales-based payments. This could potentially have a positive impact on MaxCyte's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100